Reproductive effects in animal tests: the study that triggered the ban
A 2002 study fed propylparaben to young male rats and found reduced sperm production and lower testosterone at the lowest dose tested, which was close to the previously acceptable daily intake. EFSA reviewed this finding and concluded there was no dose at which the additive clearly caused no harm to the male reproductive system, making it impossible to set a safe intake level.
Young male rats fed propylparaben showed dose-dependent reductions in daily sperm production and cauda epididymal sperm reserves. Serum testosterone also fell at the highest dose. Effects appeared at the lowest tested dose of approximately 10mg per kilogram of body weight per day.
2002AnimalOishi S, Food and Chemical Toxicology, Vol 40(12), pp.1807-1813
EFSA's Scientific Panel on food additives reviewed the para-hydroxybenzoates and concluded it could not recommend a specific ADI for propylparaben because there was no clear no-observed-adverse-effect level for the male reproductive endpoint. This exclusion from the group ADI effectively made continued food authorisation untenable.
2004Regulatory reviewEFSA Scientific Panel AFC, Opinion on para hydroxybenzoates (E 214-219), EFSA Journal 83
Contested science: later studies found no reproductive harm
Two large, rigorously controlled studies published in 2013 tested propylparaben in juvenile male rats at doses up to 1000mg per kilogram per day and found no effects on sperm, reproductive organs, or testosterone. A 2017 scientific review argued that the original Oishi study had anomalous control values and that the EU ban was not well-founded by the totality of evidence. The EFSA ban, however, remains in place.
Oral administration of propylparaben for 8 weeks starting in juvenile male Wistar rats found no effects on reproductive organ weights, sperm count or motility, or hormone levels at any dose up to 1000mg per kilogram per day. NOAEL was set at 1000mg/kg/day.
2013AnimalGazin et al., Toxicological Sciences, 136(2):392
A regulatory science review argued the Oishi 2002 control testosterone values were approximately four times higher than historical norms for the rat strain used, and that raw data were not available for audit. The review concluded the EU assessment was compromised and called for reassessment using auditable GLP data.
2017Regulatory reviewSnodin D, Human and Experimental Toxicology, 36(11), 2017
Weak hormone-mimicking activity in laboratory tests
All parabens, including propylparaben, show weak oestrogen-like activity in cell-based laboratory tests. Propylparaben can bind to oestrogen receptors and stimulate oestrogen-responsive genes in human breast cancer cells, though at concentrations far higher than oestrogen itself. Whether this laboratory activity translates to meaningful effects in people at food-relevant exposures is not established.
Propylparaben stimulated expression of oestrogen-regulated genes and increased proliferation in MCF-7 human breast cancer cells at concentrations of 1 micromolar and above, through an oestrogen receptor-mediated mechanism confirmed by an anti-oestrogen blocking agent.
2002LabByford JR et al., Journal of Steroid Biochemistry and Molecular Biology, 80(1), pp.49-60
A review of parabens' endocrine toxicity found that parabens show weak oestrogenic activity in laboratory and animal test systems, that they can penetrate human skin intact without full breakdown, and that intact parabens have been detected in human tissues. The review concluded the potential human health risks warranted further scrutiny.
2008Lab + animalDarbre PD, Harvey PW, Journal of Applied Toxicology, 28(5), pp.561-578
Detection in human breast tissue
A 2004 study detected parabens including propylparaben intact inside breast tumour samples from 19 of 20 patients. The authors noted this was significant because parabens had previously been assumed to break down rapidly in the body. The study found an association, not a cause, and its authors were explicit that no causal link to cancer could be drawn.
Intact parabens were detected in tissue samples from 19 of 20 human breast tumours by high-pressure liquid chromatography and tandem mass spectrometry. The study could not identify either the route of entry or the source of the parabens, and no causal link to tumour formation was established.
2004ObservationalDarbre PD et al., Journal of Applied Toxicology, 24(1), pp.5-13
Pregnancy exposure and child behaviour: early observational evidence
A 2026 study tracked paraben levels in pregnant women's urine across pregnancy and then assessed their children's behaviour using standardised checklists at ages two, three, and four. Higher paraben mixture exposure was linked to higher scores for externalising behaviours, particularly at age two. The findings are observational: they show an association, not proof that parabens caused the behaviour differences.
In a prospective cohort study, prenatal exposure to a paraben mixture was associated with higher scores for externalising behaviours and oppositional defiant problems in children at ages 2 and 3. Propylparaben individually was associated with reduced withdrawn behaviour scores in males at age 2. Effects were strongest in male children and at younger ages.
2026ObservationalWoodbury M, Cragoe NG, Schantz SL, Toxics, 14(3):211
Endocrine disruptor classification: the current regulatory position
The EU Scientific Committee on Consumer Safety reviewed all available evidence in 2021 and concluded that while some data suggested potential endocrine effects, the evidence was not sufficient to formally classify propylparaben as an endocrine-disrupting substance. It remains banned from food in the EU and UK regardless of this finding, because the food ban was triggered by the reproductive endpoint in the 2004 EFSA review.
The SCCS concluded in 2021 that the available data provided some indications of potential endocrine effects for propylparaben but that the current level of evidence was insufficient to regard it as an endocrine-disrupting substance or to derive a toxicological point of departure based on endocrine-disrupting properties.
2021Regulatory reviewEU Scientific Committee on Consumer Safety, SCCS/1623/20 Final Opinion